this is at our knowledge the largest real life observation concerning the use of G-CSF in R/R DLBCL patients treated with CAR-T. We observed that administering G-CSF from D5 as prophylaxis in neutropenic patients did not increase the risk of experiencing severe CRS, nor ICANS. G-CSF administration seemed not to interfere with CAR-T expansion kinetics and it was safe also in preserving CAR-T antilymphoma activity, with no impact on the quality of responses and outcomes. For these reasons, routine G-CSF administration seems to be safely considerable in the context of CAR-T treatment for R/R DLBCL.
Galli, E., Allain, V., Di Blasi, R., Bernard, S., Vercellino, L., Morin, F., Moatti, H., Caillat-Zucman, S., Chevret, S., Thieblemont, C., G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma, <<BONE MARROW TRANSPLANTATION>>, 2020; 55 (12): 2347-2349. [doi:10.1038/s41409-020-01006-x] [https://hdl.handle.net/10807/295379]
G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma
Galli, Eugenio;Di Blasi, Roberta;
2020
Abstract
this is at our knowledge the largest real life observation concerning the use of G-CSF in R/R DLBCL patients treated with CAR-T. We observed that administering G-CSF from D5 as prophylaxis in neutropenic patients did not increase the risk of experiencing severe CRS, nor ICANS. G-CSF administration seemed not to interfere with CAR-T expansion kinetics and it was safe also in preserving CAR-T antilymphoma activity, with no impact on the quality of responses and outcomes. For these reasons, routine G-CSF administration seems to be safely considerable in the context of CAR-T treatment for R/R DLBCL.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
